CGRP Education & Research Forum
Already a member? Become a member Register

Erenumab benefits in refractory chronic migraine

Erenumab may be an effective and well tolerated therapy for patients with medically refractory, chronic migraine with and without medication overuse, according to results of a prospective single centre real world audit of patients treated for six months. The 162 patients in the audit had failed a mean of 8.4 preventive treatments at baseline, and …

Read more »